Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18924370 | 0.83 | ACHE (0.50) | NAMPTKDM5BPRMT5WDR77ACHE | |
| SCHEMBL10264426 | 0.81 | NAMPT (0.40) | NAMPTKDM5BPRMT5WDR77ACHE | |
| SCHEMBL24973097 | 0.81 | NAMPT (0.40) | NAMPTKDM5BPRMT5WDR77ACHE | |
| SCHEMBL12776229 | 0.81 | L3MBTL1 (0.50) | NAMPTKDM5BPRMT5WDR77L3MBTL1 | |
| SCHEMBL16805456 | 0.81 | NAMPT (0.40) | NAMPTKDM5BPRMT5WDR77ACHE | |
| SCHEMBL26748196 | 0.78 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL15978917 | 0.77 | PDK2 (0.35) | L3MBTL1CTSDBACE1 | |
| SCHEMBL12092593 | 0.77 | MAPT (0.37) | ACHEL3MBTL1 | |
| SCHEMBL19934576 | 0.77 | NAMPT (0.40) | NAMPTKDM5BPRMT5WDR77SYK | |
| SCHEMBL22792602 | 0.77 | CYP2D6 (0.37) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189826-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | NAMPT 393/4885KDM5B 2235/4885PRMT5 1662/4885 |
| US-10189826-B2 | Heterocyclic compounds and methods of use | HRAS, VHL, ESRRB | NAMPT 596/4885KDM5B 3399/4885PRMT5 1971/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | NAMPT 393/4885KDM5B 2235/4885PRMT5 1662/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | NAMPT 596/4885KDM5B 3399/4885PRMT5 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.